Literature DB >> 20855045

National trends in child and adolescent psychotropic polypharmacy in office-based practice, 1996-2007.

Jonathan S Comer1, Mark Olfson, Ramin Mojtabai.   

Abstract

OBJECTIVE: To examine patterns and recent trends in multiclass psychotropic treatment among youth visits to office-based physicians in the United States.
METHOD: Annual data from the 1996-2007 National Ambulatory Medical Care Surveys were analyzed to examine patterns and trends in multiclass psychotropic treatment within a nationally representative sample of 3,466 child and adolescent visits to office-based physicians in which a psychotropic medication was prescribed.
RESULTS: There was an increase in the percentage of child visits in which psychotropic medications were prescribed that included at least two psychotropic classes. Across the 12 year period, multiclass psychotropic treatment rose from 14.3% of child psychotropic visits (1996-1999) to 20.2% (2004-2007) (adjusted odds ratio [AOR] = 1.89, 95% confidence interval [CI] = 1.22-2.94, p < .01). Among medical visits in which a current mental disorder was diagnosed, the percentage with multiclass psychotropic treatment increased from 22.2% (1996-1999) to 32.2% (2004-2007) (AOR = 2.23, 95% CI = 1.42-3.52, p < .001). Over time, there were significant increases in multiclass psychotropic visits in which ADHD medications, antidepressants, or antipsychotics were prescribed, and a decrease in those visits in which mood stabilizers were prescribed. There were also specific increases in co-prescription of ADHD medications and antipsychotic medications (AOR = 6.22, 95% CI = 2.82-13.70, p < .001) and co-prescription of antidepressant and antipsychotic medications (AOR = 5.77, 95% CI = 2.88-11.60, p < .001).
CONCLUSIONS: Although little is known about the safety and efficacy of regimens that involve concomitant use of two or more psychotropic agents for children and adolescents, multiclass psychotropic pharmacy is becoming increasingly common in outpatient practice.
Copyright © 2010 American Academy of Child and Adolescent Psychiatry. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20855045      PMCID: PMC2952543          DOI: 10.1016/j.jaac.2010.07.007

Source DB:  PubMed          Journal:  J Am Acad Child Adolesc Psychiatry        ISSN: 0890-8567            Impact factor:   8.829


  63 in total

Review 1.  When is antipsychotic polypharmacy supported by research evidence? Implications for QI.

Authors:  Jessica L Gören; Joseph J Parks; Frank A Ghinassi; Celeste G Milton; John M Oldham; Pablo Hernandez; Jeffrey Chan; Richard C Hermann
Journal:  Jt Comm J Qual Patient Saf       Date:  2008-10

2.  The effects of methylphenidate and lithium on attention and activity level.

Authors:  G A Carlson; M D Rapport; K L Kelly; C S Pataki
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  1992-03       Impact factor: 8.829

3.  Concomitant use of atomoxetine and OROS-methylphenidate in a 10-year-old child suffering from attention-deficit/hyperactivity disorder with comorbid bipolar disorder and Tourette syndrome.

Authors:  Sol Jaworowski; Fortu Benarroch; Varda Gross-Tsur
Journal:  J Child Adolesc Psychopharmacol       Date:  2006-06       Impact factor: 2.576

4.  Clinical relevance of the primary findings of the MTA: success rates based on severity of ADHD and ODD symptoms at the end of treatment.

Authors:  J M Swanson; H C Kraemer; S P Hinshaw; L E Arnold; C K Conners; H B Abikoff; W Clevenger; M Davies; G R Elliott; L L Greenhill; L Hechtman; B Hoza; P S Jensen; J S March; J H Newcorn; E B Owens; W E Pelham; E Schiller; J B Severe; S Simpson; B Vitiello; K Wells; T Wigal; M Wu
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2001-02       Impact factor: 8.829

5.  National trends in the use of psychotropic medications by children.

Authors:  Mark Olfson; Steven C Marcus; Myrna M Weissman; Peter S Jensen
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2002-05       Impact factor: 8.829

6.  Trends in the prescribing of psychotropic medications to preschoolers.

Authors:  J M Zito; D J Safer; S dosReis; J F Gardner; M Boles; F Lynch
Journal:  JAMA       Date:  2000-02-23       Impact factor: 56.272

7.  A double-blind pilot study of risperidone in the treatment of conduct disorder.

Authors:  R L Findling; N K McNamara; L A Branicky; M D Schluchter; E Lemon; J L Blumer
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2000-04       Impact factor: 8.829

8.  Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents With Depression Study (TADS) randomized controlled trial.

Authors:  John March; Susan Silva; Stephen Petrycki; John Curry; Karen Wells; John Fairbank; Barbara Burns; Marisa Domino; Steven McNulty; Benedetto Vitiello; Joanne Severe
Journal:  JAMA       Date:  2004-08-18       Impact factor: 56.272

9.  Trends in polypharmacy and potential drug-drug interactions across educational groups in elderly patients in Sweden for the period 1992 - 2002.

Authors:  S I Haider; K Johnell; M Thorslund; J Fastbom
Journal:  Int J Clin Pharmacol Ther       Date:  2007-12       Impact factor: 1.366

10.  A pilot study of risperidone, olanzapine, and haloperidol in psychotic youth: a double-blind, randomized, 8-week trial.

Authors:  Linmarie Sikich; Robert M Hamer; Robert A Bashford; Brian B Sheitman; Jeffrey A Lieberman
Journal:  Neuropsychopharmacology       Date:  2004-01       Impact factor: 7.853

View more
  86 in total

1.  Polypharmacy in attention deficit hyperactivity disorder treatment: current status, challenges and next steps.

Authors:  Regina Bussing; Almut G Winterstein
Journal:  Curr Psychiatry Rep       Date:  2012-10       Impact factor: 5.285

2.  Open-label adjunctive creatine for female adolescents with SSRI-resistant major depressive disorder: a 31-phosphorus magnetic resonance spectroscopy study.

Authors:  Douglas G Kondo; Young-Hoon Sung; Tracy L Hellem; Kristen K Fiedler; Xianfeng Shi; Eun-Kee Jeong; Perry F Renshaw
Journal:  J Affect Disord       Date:  2011-08-09       Impact factor: 4.839

3.  Risperidone added to parent training and stimulant medication: effects on attention-deficit/hyperactivity disorder, oppositional defiant disorder, conduct disorder, and peer aggression.

Authors:  Kenneth D Gadow; L Eugene Arnold; Brooke S G Molina; Robert L Findling; Oscar G Bukstein; Nicole V Brown; Nora K McNamara; E Victoria Rundberg-Rivera; Xiaobai Li; Heidi L Kipp; Jayne Schneider; Cristan A Farmer; Jennifer L Baker; Joyce Sprafkin; Robert R Rice; Srihari S Bangalore; Eric M Butter; Kristin A Buchan-Page; Elizabeth A Hurt; Adrienne B Austin; Sabrina N Grondhuis; Michael G Aman
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2014-06-12       Impact factor: 8.829

Review 4.  Metabolic and cardiovascular adverse effects associated with antipsychotic drugs.

Authors:  Marc De Hert; Johan Detraux; Ruud van Winkel; Weiping Yu; Christoph U Correll
Journal:  Nat Rev Endocrinol       Date:  2011-10-18       Impact factor: 43.330

5.  Trends in laboratory test volumes for Medicare Part B reimbursements, 2000-2010.

Authors:  Shahram Shahangian; Todd D Alspach; J Rex Astles; Ajay Yesupriya; William K Dettwyler
Journal:  Arch Pathol Lab Med       Date:  2013-06-05       Impact factor: 5.534

6.  Possible mechanisms for the skeletal effects of antipsychotics in children and adolescents.

Authors:  Chadi A Calarge; Stephanie D Ivins; Katherine J Motyl; Amal A Shibli-Rahhal; Michael M Bliziotes; Janet A Schlechte
Journal:  Ther Adv Psychopharmacol       Date:  2013-10

7.  Evidence-based psychological treatments for mental disorders: modifiable barriers to access and possible solutions.

Authors:  Allison G Harvey; Nicole B Gumport
Journal:  Behav Res Ther       Date:  2015-02-26

8.  Psychotropic use in children and adolescents in Scandinavia and Catalonia: a 10-year population-based study.

Authors:  Ainhoa Gómez-Lumbreras; Ana Garcia Sangenis; Oriol Prat Vallverdú; Anna Gatell Carbó; Cristina Vedia Urgell; Laura Gisbert Gustemps; Xavier Bruna Pérez; Antoni Ramos Quiroga; Rosa Morros Pedrós
Journal:  Psychopharmacology (Berl)       Date:  2021-03-10       Impact factor: 4.530

Review 9.  Evidence-based treatments for youths with severely dysregulated mood: a qualitative systematic review of trials for SMD and DMDD.

Authors:  Xavier Benarous; Angèle Consoli; Jean-Marc Guilé; Sébastien Garny de La Rivière; David Cohen; Bertrand Olliac
Journal:  Eur Child Adolesc Psychiatry       Date:  2016-09-23       Impact factor: 4.785

Review 10.  Antipsychotic and psychostimulant drug combination therapy in attention deficit/hyperactivity and disruptive behavior disorders: a systematic review of efficacy and tolerability.

Authors:  David Linton; Alasdair M Barr; William G Honer; Ric M Procyshyn
Journal:  Curr Psychiatry Rep       Date:  2013-05       Impact factor: 5.285

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.